Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 10/20 | 0.48 |
| ▸ | DRD2 | P14416 | 7/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.48 |
| ▸ | DRD1 | P21728 | 5/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.48 |
| ▸ | HTR2A | P28223 | 4/20 | 0.48 |
| ▸ | HTR2C | P28335 | 4/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.48 |
| ▸ | HRH1 | P35367 | 4/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.48 |
| ▸ | HTR2B | P41595 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.48 |
| ▸ | DRD4 | P21917 | 3/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4837066 | 1.00 | CHRM1 (0.48) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| SCHEMBL14528276 | 0.92 | CHRM1 (0.47) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| SCHEMBL4843951 | 0.89 | CHRM1 (0.37) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| SCHEMBL4843943 | 0.89 | CHRM1 (0.37) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| SCHEMBL14156723 | 0.89 | CHRM1 (0.63) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL4846129 | 0.88 | CHRM1 (0.62) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL4847048 | 0.88 | CHRM1 (0.62) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL4846113 | 0.88 | CHRM1 (0.62) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL4847060 | 0.88 | CHRM1 (0.62) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| SCHEMBL4840387 | 0.86 | CHRM1 (0.50) | CHRM1DRD2CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384934-B2 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384934-B2 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384934-B2 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1546134-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1546134-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | GABBR1, GABBR2, GABRA5 | CHRM1 302/4885DRD2 7/4885CHRM2 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.